Biossil raises $153M; CEO confirms building integrated AI biotech infrastructure

Biossil secured $153 million USD in an all-equity funding round at a $1 billion valuation, led by the OpenAI Startup Fund. The capital infusion is designed to expand the firm’s clinical development capacity and accelerate its ability to acquire more drug candidates for its pipeline.

However, CEO Anthony Mouchantaf highlighted a critical constraint facing the industry. He stated that biomedical insights generated by AI must be translated into physical medicine to benefit patients. Achieving this requires building dedicated infrastructure capable of integrating AI and medicine across the entire spectrum: from initial discovery through clinical development and into patient care. Biossil confirmed it is actively building this integrated system in both the United States and Canada.

This focus on physical, end-to-end infrastructure represents a significant capital pivot for Canadian biotech firms. While many AI companies are applying their models to healthcare data, Biossil’s stated goal involves creating tangible assets, the labs and processes necessary to move molecules from computational prediction into clinical reality. This places the operational burden on building integrated facilities rather than solely relying on software advancements.

The market is already demonstrating this trend: Anthropic has established a biolab in California, and Cohere recently acquired biopharma data processing startup Reliant AI. Biossil’s capital raise and commitment to dual-jurisdiction infrastructure build-out confirm that the next competitive frontier for biotech investment is not just superior algorithms, but the physical capacity to execute on those algorithmic discoveries.